Ms. Iris Bincovich reports

INNOCAN REPORTS SUCCESSFUL PRECLINICAL DOG-TRIAL RESULTS REGARDING PAIN MANAGEMENT: "IT WAS AS IF A NEW DOG CAME INTO OUR LIVES"

Innocan Pharma Corp. has successfully preclinical trials in dogs with osteoarthritis. A case entailing the clinical condition of Goody, an eight-year-old male mixed-breed dog, who was rescued in a terrible condition after he was found tied up with a very short leash, cachectic and wounded, was published. Goody suffers from severe osteoarthritis in most of his joints, and severe muscle atrophy, mostly surrounding the pelvic limbs. Goody was already treated with joint supplements, non-steroidal anti-inflammatory drugs and hydrotherapy. The liposomal CBD was administered on top of these treatments.

Goody's (the dog) owners said: "We adopted Goody as a dog that has a lot of joint problems. During July, 2021, his condition became worse making him incapable of rising without performing on him joint warmup and massage. It was sad seeing him unable to enjoy life. After Goody received the liposomal CBD injections, it was as if a new dog came into our lives. He gets up all the time and enjoys life more than ever. We even complain sometimes that he gets up too much. He has this smile all the time as if he is enjoying himself and we could not be happier."

"The global pain management drugs market reached a value of $65.4-billion (U.S.) in 2021. Looking forward, IMARC Group expects the market to reach $82.1-billion (U.S.) by 2027, exhibiting a CAGR [compound annual growth rate] of 3.8 per cent during 2022 to 2027."

"Putting an end to the misery of patients is life's ultimate calling," said Iris Bincovich, chief executive officer of Innocan, and added, "We couldn't be more honored to prove our clinical standing, together with our R&D labs, and to move and major step towards the market."

Innocan's unique solution

By administering CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting and significant levels of CBD in the body, which Innocan believes will create a far more effective and continuous therapeutic effect.

Innocan carried out a series of experiments of its LPT platform on animals. These experiments have demonstrated initial positive results, validating the viability of Innocan's intention to make CBD available to humans and animals for extended periods upon a single dosage.

Innocan's unique delivery method allows for the controlled release of CBD into the bloodstream with improved pharmacokinetic (PK) performance. The research was conducted in collaboration with the Hebrew University of Jerusalem and indicates potential for the company's technology to deliver cannabinoids to the blood stream in an effective manner.

Innocan's relationship with The Hebrew University

Innocan Pharma Ltd., a wholly owned subsidiary of the company, has entered into a worldwide exclusive research and licence agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of sustained release products of CBD (or other cannabinoids). The research and development initiative is led by Prof. Chezy Barenholz, head of the membrane and liposome research department at The Hebrew University, which is the inventor of over 55 patent families, two of which underlie Doxil, a Food and Drug Administration-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this technology on Oct. 7, 2019.

About Innocan Pharma Corp.

Innocan is a pharmaceutical technology company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Innocan Pharma signed a worldwide exclusive licence agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled-release liposome to be administered by injection. Innocan Israel plans, together with Prof. Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Pharma each have commercially successful records in the pharmaceutical and technology sectors in Israel and globally.

We seek Safe Harbor.